FDA adds suicide studies to drug trials

Share this article:

The FDA has quietly started asking many drug companies to look at whether drugs in clinical trials cause some patients to become suicidal.

The New York Times reported in January that the agency has not announced the change publicly because its oversight of experimental medicines is done in secret. But makers of drugs to treat obesity, urinary incontinence, epilepsy, smoking cessation, depression and many other conditions are being asked to put a comprehensive suicide assessment into their clinical trials.

The FDA would not tell the Times how many letters it has sent in recent months to drug manufacturers requiring them to use a suicide assessment. Many are using a scale developed at Columbia University during work funded by FDA to reanalyze data from antidepressant clinical trials when concern was first raised that those drugs cause some children and teens to become suicidal.

Soon, the newspaper said, FDA reviewers were seeing potential psychiatric effects in reports of trials for drugs in other therapeutic classes and the agency began to look at the issue more broadly.

The Times said that among medicines still for sale, the FDA has determined the benefits outweigh any psychiatric risks. But the agency now wants to uncover such problems more reliably and before approval. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete October 2014 Digital Edition

Read the complete October 2014 Digital Edition

Click the above link to access the complete Digital Edition of the October 2014 issue of MM&M, with all text, charts and pictures.

Predicting your pink slip

Predicting your pink slip

Any time a firm needs to save money, high-salaried executives are targets

Private View: New ways to engage with customers

Private View: New ways to engage with customers

These healthcare social media campaigns successfully use emotion, altruism and the human desire to "brand" oneself to get customers engaged.